Evidence map›Paper›PMID 40477696›Full record

ReviewOpenNano

State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic.

Rahul Bhattacharjee, Ankit Kumar Dubey, Archisha Ganguly, Basudha Bhattacharya, Yogendra Kumar Mishra, Ebrahim Mostafavi, Ajeet Kaushik

Abstract readReview
In one paragraph

Review in OpenNano. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Biofabrication of Nanosilver FromInternational journal of food science · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rahul BhattacharjeeKIIT School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT-DU), Bhubaneswar, Odisha, India.
Ankit Kumar DubeyInstitute of Scholars, Chikmagalur, Karnataka 577102, India.
Archisha GangulySchool of Biology, Indian Institute of Science Education and Research, Thiruvananthapuram, India.
Basudha BhattacharyaKIIT School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT-DU), Bhubaneswar, Odisha, India.
Yogendra Kumar MishraMads Clausen Institute, NanoSYD, University of Southern Denmark, Alsion 2, 6400, Sønderborg, Denmark.
Ebrahim MostafaviStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Ajeet KaushikNanoBioTech Laboratory, Department of Environmental Engineering, Florida Polytechnic University, Lakeland, FL 33805, United States.

Funding

Multi-Disciplinary Training Program in Cardiovascular Imaging at StanfordT32EB009035 · NIBIB · STANFORD UNIVERSITY · PI Koen Nieman, John M. Pauly · 2008 to 2026
$4.3M
NIBIB NIH HHS T32 EB009035
6 · The paper itself

Abstract

The emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants made emerging novel coronavirus diseases (COVID-19) pandemic/endemic/or both more severe and difficult to manage due to increased worry about the efficacy and efficiency of present preventative, therapeutic, and sensing measures. To deal with these unexpected circumstances, the development of novel nano-systems with tuneable optical, electrical, magnetic, and morphological properties can lead to novel research needed for (1) COVID-19 infection (anti-microbial systems against SARS-CoV-2), (2) early detection of mutated SARS-CoV-2, and (3) targeted delivery of therapeutics using nano-systems, i.e., nanomedicine. However, there is a knowledge gap in understanding all these nano-biotechnology potentials for managing mutated SARS-CoV-2 on a single platform. To bring up the aspects of nanotechnology to tackle SARS-CoV-2 variants related COVID-19 pandemic, this article emphasizes improvements in the high-performance of nano-systems to combat SARS-CoV-2 strains/variants with a goal of managing COVID-19 infection via trapping, eradication, detection/sensing, and treatment of virus. The potential of state-of-the-art nano-assisted approaches has been demonstrated as an efficient drug delivery systems, viral disinfectants, vaccine productive cargos, anti-viral activity, and biosensors suitable for point-of-care (POC) diagnostics. Furthermore, the process linked with the efficacy of nanosystems to neutralize and eliminate SARS-CoV-2 is extensively highligthed in this report. The challenges and opportunities associated with managing COVID-19 using nanotechnology as part of regulations are also well-covered. The outcomes of this review will help researchers to design, investigate, and develop an appropriate nano system to manage COVID-19 infection, with a focus on the detection and eradication of SARS-CoV-2 and its variants. This article is unique in that it discusses every aspect of high-performance nanotechnology for ideal COVID pandemic management.

Indexed as

Anti-viral nano-systemBiosensorsCOVID-19 managementDrug delivery systemsMutated SARS-CoV-2Nano-biotechnologyNanomedicine

Identifiers

PMID40477696
PMCPMC9463543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.